Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 12/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.58 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31103612 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Bromide SCHEMBL238105 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Bromide SCHEMBL11903700 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Bromide SCHEMBL11546904 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Bromide SCHEMBL320636 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Bromide SCHEMBL5594917 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Mecetronium SCHEMBL60918 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Mecetronium SCHEMBL675420 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Bromide SCHEMBL21253152 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A | |
| Bromide SCHEMBL31103710 | 1.00 | DNM1 (1.00) | DNM1HSP90AA1RAD52HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 988 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022012-A1 | METHOD FOR CATALYTICALLY DRY REFORMING METHANE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2026-01-22 | — | — | US | claimed |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2026-01-08 | — | — | US | claimed |
| US-20250281910-A1 | FIBROUS SILICA LANTHANUM OXIDE-BASED CATALYST FOR DRY REFORMING OF METHANE AND METHODS OF PREPARATION THEREOF | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-09-11 | — | — | US | claimed |
| CN-116786162-B | Preparation method and application of modified silicon dioxide particles as triboelectric catalyst | 电子科技大学(深圳)高等研究院 | 2025-06-13 | — | — | CN | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-12215025-B1 | Fibrous silica zinc oxide-supported nickel catalyst for dry reforming of methane and methods of preparation thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-02-04 | — | — | US | claimed |
| CN-119350818-A | Degradable medical liquid storage bag material and preparation method thereof | 上海乐纯佰鑫生物新材料科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-114920954-B | High-strength and high-toughness swelling-resistant supermolecule conductive hydrogel and preparation method and application thereof | 广东工业大学 | 2024-12-06 | — | — | CN | claimed |
| CN-114269744-B | Methods for preparing Toll-like receptor modulator compounds | 吉利德科学公司 | 2024-10-18 | — | — | CN | claimed |
| CN-118639465-A | Water-based coating material for plastic-free paper, preparation method and application thereof | 广东工业大学 | 2024-09-13 | — | — | CN | claimed |
| US-20040009655-A1 | Method for manufacturing metal line contact plugs for semiconductor devices | HYNIX SEMICONDUCTOR INC. (KR) | 2004-01-15 | — | — | US | claimed |
| EP-1354036-A2 | COMPOSITIONS, METHODS, AND KITS FOR ISOLATING NUCLEIC ACIDS USING SURFACTANTS AND PROTEASES | Applera Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020177139-A1 | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | APPLIED BIOSYSTEMS, LLC | 2002-11-28 | — | — | US | claimed |
| WO-2002090539-A2 | COMPOSITIONS, METHODS, AND KITS FOR ISOLATING NUCLEIC ACIDS USING SURFACTANTS AND PROTEASES | APPLERA CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | claimed |
| US-6136972-A | Preparation of a mannich base intermediate for 2-[(4-heterocyclic-phenoxymethyl)-phenoxy]-alkanoates | FMC CORPORATION (US) | 2000-10-24 | — | — | US | claimed |
| EP-0217197-B1 | DETERMINATION OF BILIRUBIN AND CORRESPONDING REAGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1991-10-16 | — | — | EP | claimed |
| US-4849531-A | Process for the preparation of 2,3-epoxyamides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | claimed |
| US-4745071-A | QUANTITATIVE ANALYSIS FOR LEUKOCYTES | SEQUOIA-TURNER CORPORATION (US) | 1988-05-17 | — | — | US | claimed |
| US-4711959-A | REACTING 2-ALKYLSULPHONYL-PYRIMIDINE WITH CYANAMIDE OR METAL SALT OF CYANAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1987-12-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022012-A1 | METHOD FOR CATALYTICALLY DRY REFORMING METHANE | RNF4, SOD1, HRH4 | DNM1 650/4885HSP90AA1 3095/4885RAD52 592/4885 |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | CD14, CD47, MYD88 | DNM1 2280/4885HSP90AA1 1473/4885RAD52 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.